Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting

Abstract Purpose The therapeutic landscape of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC) has evolved considerably with the introduction of newer targeted agents and their combinations with endocrine therapies. In this sce...

Full description

Bibliographic Details
Main Authors: Shaheenah Dawood, Maria Konstantionva, Rebecca Dent, Florencia Perazzo, Sung-Bae Kim, Cynthia Villarreal-Garza, Sandra Franco, Ming-Shen Dai, Sergio Simon
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Proceedings
Subjects:
Cyclin-dependent kinase 4/6 inhibitor
Endocrine therapy
Hormone receptor-positive
Human epidermal growth factor receptor 2 negative
Metastatic breast cancer PI3K/mTOR inhibitor
Registry
Online Access:https://doi.org/10.1186/s12919-021-00224-5

Internet

https://doi.org/10.1186/s12919-021-00224-5

Similar Items